XML 33 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Stock Option Plans and Warrants to Purchase Common Stock
12 Months Ended
Dec. 31, 2020
Share-based Payment Arrangement [Abstract]  
Stock Option Plans and Warrants to Purchase Common Stock

Note 10. Stock Option Plans and Warrants to Purchase Common Stock


Stock Option Plans


The Amended and Restated 2005 Equity Incentive Plan (“2005 Plan”) was replaced by the 2015 Plan, which was approved in June 2015. No securities are available for future issuance under the 2005 Plan. As of December 31, 2020, approximately 214,689 shares are available for grants under the 2015 Plan, and are divided into four separate equity programs:


  1) the Discretionary Option Grant Program, under which eligible persons may, at the discretion of the Plan Administrator, be granted options to purchase shares of common stock,

  2) the Salary Investment Option Grant Program, under which eligible employees may elect to have a portion of their base salary invested each year in options to purchase shares of common stock,

  3) the Automatic Option Grant Program, under which eligible nonemployee Board members will automatically receive options at periodic intervals to purchase shares of common stock, and

  4) the Director Fee Option Grant Program, under which non-employee Board members may elect to have all, or any portion, of their annual retainer fee otherwise payable in cash applied to a special option grant.

Shares available for grant under the 2015 Plan were as follows:


Shares available for grant at January 1, 2020   663,709 
Options granted   (520,812)
Options forfeited   71,792 
Shares available for grant at December 31, 2020   214,689 

Activity under the 2005 Plan and the 2015 Plan for the years ended December 31, 2020 and 2019 was as follows:


       Weighted
Average
 
   Options   Options
Exercise
Price
 
Balance outstanding at December 31, 2018   1,022,095   $5.32 
Granted   596,740    1.09 
Forfeited   (111,863)   3.27 
Balance outstanding at December 31, 2019   1,506,972   $3.77 
Granted   520,812    2.17 
Forfeited   (88,222)   13.06 
Exercised   (5,758)   1.19 
Balance outstanding at December 31, 2020   1,933,804   $2.96 

As of December 31, 2020, there were 1,310,442 options exercisable with a weighted average exercise price of $3.53 and a weighted average remaining contractual term of 7.24 years. As of December 31, 2020, there were 1,933,804 options outstanding with a weighted average exercise price of $2.96 and remaining term of 7.91 years.


The Company awarded 520,812 and 596,740 stock options during the years ended December 31, 2020 and 2019, respectively, which had a weighted average grant date fair value per share of $0.97 and $0.68, respectively. The weighted-average exercise price, by price range, for outstanding options to purchase common stock at December 31, 2020 was:


 

Price Range

 

Weighted
Average
Remaining

Contractual
Life in Years

  

Outstanding

Options

  

Exercisable

Options

 
$0.71-$2.79   8.49    1,723,180    1,099,818 
$6.40-$15.60   3.42    156,394    156,394 
$20.00-$39.80   2.58    54,230    54,230 
Total   7.91    1,933,804    1,310,442 

The Company’s share-based compensation expense for the years ended December 31, 2020 and 2019 was recognized as follows:


Share-based compensation  2020   2019 
Research and development  $195,560   $143,217 
General and administrative   214,373    233,122 
Total  $409,933   $376,339 

At December 31, 2020, the total compensation cost for stock options not yet recognized was approximately $584,000 and will be expensed over the next three years.


Warrants to Purchase Common Stock


Warrant activity for the years ended December 31, 2020 and 2019 was as follows:


   Warrants  

Weighted
Average

Exercise
Price

 
Balance at December 31, 2018   6,303,643   $3.09 
Granted    -    - 
Exercised   -    - 
Expired   (110,932)   14.80 
Balance at December 31, 2019   6,192,711   $2.88 
Granted   -    - 
Exercised   (461,234)   1.87 
Expired   -    - 
Balance at December 31, 2020   5,731,477   $2.96 

F-20


The remaining life, by grant date, for outstanding warrants at December 31, 2020 was:


 

Grant Date

  Exercise
Price
   Remaining
Contractual
Life in Years
   Outstanding
Warrants
   Exercisable
Warrants
 
12/16/2016  $3.95    0.96    2,403,405    2,403,405 
11/3/2017  $2.50    1.83    49,872    49,872 
4/1/2018  $1.95    2.24    10,000    10,000 
7/2/2018  $2.25    1.01    3,268,200    3,268,200 
Total  $2.88    2.02    5,731,477    5,731,477